Suraksha Diagnostic credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
1.71.75.8
−24.6−24.6−14.3
0.01×0.01×0.03×
−0.10×−0.10×−0.07×
0.02×0.02×0.07×
−0.24×−0.26×−0.18×
4.30×4.30×5.48×
0.7%0.7%2.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SURAKSHA₹319.55

Suraksha Diagnostic Limited

· Pharma & Health
₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,664 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt5.81.71.7
Net Debt-14.3-24.6-24.6
Total Debt/Equity0.030.010.01
Net Debt/Equity-0.07-0.10-0.10
Total Debt/EBITDA0.070.020.02
Net Debt/EBITDA-0.18-0.26-0.24
Interest Coverage (EBIT/Interest)5.484.304.30
Total Debt/Total Capital %2.700.710.71
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.